On Motley Fool Hidden Gems Investing, hosts Travis Hoy, Lou Whiteman, and Rachel Warren discuss a potential pharmaceutical mega-merger, the implications of rising interest rates, and key earnings reports on their radar for the week.
**AstraZeneca and Bristol-Myers Squibb Merger Talk**
The show opens with news of a potential merger between AstraZeneca and Bristol-Myers Squibb, a deal that would significantly shake up the pharmaceutical industry.
Rachel Warren expresses perplexity and skepticism. She notes that AstraZeneca already boasts a strong organic growth profile, projected to hit $80 billion in annual sales by 2030, and doesn't "necessarily need" such a merger. The acquisition would force AstraZeneca to absorb Bristol-Myers Squibb's looming patent cliff on key assets like Eliquis, potentially diluting AstraZeneca's oncology-driven growth. Rachel also highlights potential antitrust roadblocks, as both companies are powerhouses in cancer care, likely triggering red flags from the FTC and European regulators. While AstraZeneca might seek increased U.S. exposure (Bristol-Myers Squibb derives 69% of revenue from the U.S. vs. AstraZeneca's 42%), Rachel points out that historical pharmaceutical mega-mergers frequently destroy shareholder value. Financially, neither company has the independent balance sheet capacity for a straight cash and debt buyout, making such a deal essentially impossible.
Lou Whiteman agrees that this isn't "smart M&A," calling it "size for the sake of size." He argues that the deal is "not in the public good" due to significant product overlap; both companies compete in cancer and immunotherapy with pipelines chasing similar targets. Such a merger would inevitably lead to promising molecules being shelved. Lou proposes a theory for why the news is circulating: a perception that the current administration is merger-friendly. He believes companies are rushing to initiate deals now, hoping to finalize them ahead of the 2028 election cycle, as "now is when the getting is good." Travis Hoy concludes this segment by expressing concern over reduced competition in the pharma industry, both for consumer products and research.
**Interest Rates and Fed Credibility**
The discussion then shifts to interest rates, which have seen a significant shift from expectations of rate cuts at the beginning of the year to potential rate hikes now. Travis Hoy notes that 10-year and 30-year U.S. Treasury rates are at highs not seen since 2007 or 2004, impacting borrowing costs for companies and discount rates for stock valuations.
Lou Whiteman states that the actual level of rates, while higher, is within "normal bounds" of the last 50 years and manageable for healthy businesses. His primary concern is the **credibility of the Federal Reserve**. He argues that the market's long-held belief in the Fed as "Captain America," ready to step in and save the day, has been shaken. Lou posits that if the Fed had raised rates by 25 basis points last week instead of holding steady, long-term rates might have actually fallen due to restored credibility. He believes the Fed's "superpower is talking a big game," and with its "aura gone," investors should expect more volatility as the "Fed put" (the perceived safety net) is no longer guaranteed.
Rachel Warren highlights a divergence between the bond market (surging yields, higher borrowing costs) and the stock market (trading near record highs, seemingly ignoring high rates). She worries that heavy spending by a few giant tech firms in AI and digital infrastructure might be "hiding a broader slowdown" in the general economy, while everyday consumers face severe pressures from rising borrowing costs. Rachel also points out that under its new leader, the Fed has intentionally cut back on predictable policy clues, making market reactions less certain. She notes that despite the Fed holding rates steady last week, three regional Fed presidents strongly voted for an immediate hike, and 61-68% of the market expects two or more rate hikes before year-end.
Lou Whiteman pushes back slightly on the "different stories" narrative, suggesting the bond market is reacting to long-term uncertainty and faith in the U.S. government, not the short-term economic outlook, while the stock market focuses on earnings potential. Travis Hoy adds that much of the AI build is debt-fueled, and rising rates increase these costs, emphasizing that companies must now "actually generate a return on that investment."
**Weekly Radar**
Looking ahead to a busy earnings week:
* **Rachel** is watching for "valuation tests for AI demand" from companies like Palantir and Advanced Micro Devices (AMD), the latter projected for 47% year-over-year revenue growth. She's also tracking SpaceX's cash flow from Starlink to support AI computing network expenditures, and consumer spending metrics from companies like Walt Disney and Berkshire Hathaway, noting a cautious tone set by early reports from Marriott and Tyson Foods.
* **Lou** advises not to "sleep on" the long-end rate curve story for its long-term implications. For SpaceX, he's less interested in current numbers and more in Elon Musk's "tone" (following a somber Tesla call) and his articulation of a "near term vision" beyond marketing documents, believing a strong narrative could benefit the stock.
* **Travis** is looking at Uber, an "overlooked" company with steady 20% annual growth, to see if it can continue compounding and if there's any real threat from competitors like Waymo.
The show concludes with the standard disclaimers about personal investments and editorial standards.